Related Experiment Video
Updated: Aug 4, 2026

Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis
Published on: July 4, 2007
Eosinophilic Granulomatosis with Polyangiitis Relapse after COVID-19 Vaccination: A Case Report
Giulia Costanzo1, Andrea Giovanni Ledda1, Alessandra Ghisu1
1Department of Medical Sciences and Public Health, University of Cagliari, 09131 Cagliari, Italy.
Background:
We here describe the case of a 71-year-old Caucasian woman previously diagnosed with Eosinophilic Granulomatosis with Polyangiitis (EGPA) that had been treated with Mepolizumab, an anti-IL5 monoclonal antibody, since 2019 with a good clinical response.
Methods:
She had a mild COVID-19 in December 2020 and she tested negative for SARS-CoV-2 infection in only late January 2021. In April 2021 she received the first dose of mRNA BNT162b2 vaccine. Ten days later she developed myalgia, dyspnea and numbness of the limbs due to a relapse of EGPA that occurred during Mepolizumab treatment.
Related Concept Videos
Vaccinations
Allergic Drug Reactions
Allergic Reactions: Anaphylaxis
Hypersensitivity Reactions: Cytolytic Reactions
Vaccines
Hypersensitivity Reactions: Immune-Complex Reactions

